How have NRSNW shares performed in 2024?

NeuroSense Therapeutics' stock was trading at $0.0781 on January 1st, 2024. Since then, NRSNW shares have increased by 124.3% and is now trading at $0.1752. View the best growth stocks for 2024 here .

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRSNW

NeuroSense Therapeutics (NRSNW) Stock Price, News & Analysis

→ [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad)

Free NRSNW Stock Alerts

$0.18

0.00 (0.00%)

(As of 05/10/2024 ET)

Compare

Today's Range: $0.18
▼
$0.18
50-Day Range: $0.18
▼
$0.55
52-Week Range: $0.07
▼
$0.65

Volume: 100 shs
Average Volume: 10,104 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get NeuroSense Therapeutics alerts:

Ad Chaikin Analytics

Missed NVDA? Buy this AI stock NOW

After Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.

You can watch it here.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSNW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRSNW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive NRSNW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NRSNW
CUSIP: N/A
CIK: 1875091
Web: N/A
Phone: 972-9-799-6183
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Or Eisenberg (Age 43)
Chief Financial Officer
Comp: $382k
Dr. Ferenc Tracik M.D. (Age 60)
Chief Medical Officer
Comp: $532k
Mr. Alon Ben-Noon (Age 45)
Co-Founder, CEO & Director
Comp: $619k
Ms. Hagit Binder (Age 46)
Chief Operation Officer
Dr. Niva Russek-Blum Ph.D. (Age 45)
Chief Technology Officer
Ms. Yael Barak (Age 54)
VP of Quality & Compliance
Ms. Keren Pushett
Head of HR
Mr. Eidan Loushi
C.R.A.

Key Competitors

View All Competitors

NRSNW Stock Analysis - Frequently Asked Questions

How have NRSNW shares performed in 2024?: NeuroSense Therapeutics' stock was trading at $0.0781 on January 1st, 2024. Since then, NRSNW shares have increased by 124.3% and is now trading at $0.1752.
View the best growth stocks for 2024 here.
How do I buy shares of NeuroSense Therapeutics?: Shares of NRSNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRSNW) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial